Tag: hyperparathyroidism
First enrolment in trial of secondary hyperparathyroidism drug for ESKD patients
Pathalys Pharma and Launch Therapeutics have announced that the first patient has been enrolled in the PATH (PTH Attenuation Trial in Hemodialysis) clinical programme,...